2027-AD-HOC-GROUP
26.1.2024 10:01:31 CET | Business Wire | Press release
The 2027 Ad Hoc Group (the Group) announced today it has formed to explore options over the proposed acquisition of the Farfetch business by Coupang. The Group is comprised of institutional investors with combined AUM of over US$1 trillion, holding over 50% of Farfetch’s 3.75% Convertible Senior Notes due 2027.
The Group has appointed Pallas Partners as legal counsel and Ducera Partners, an investment bank, as financial advisors, to urgently evaluate options to protect its interests in the face of the value destruction that it believes will be effected should the Coupang sale go ahead.
As a first step, Group members have declared a default under the 2027 Notes and accelerated those Notes, so they are immediately due and payable in full. The default arose from the suspension of trading and delisting of Farfetch from the New York Stock Exchange, which was imposed by the NYSE as a result of the proposed sale to Coupang.
The Group has serious concerns about how Farfetch went from guiding the market to YE 2023 liquidity of over US$800 million in August 2023, to a distressed sale four months later. At the time of the announcement of the agreement, analyst consensus (including its house broker JPMorgan) estimated Farfetch’s enterprise value to be in excess of US$3 billion. As such, the Group is seriously concerned by the rapid and unexplained deterioration in the financial position of Farfetch between August and December 2023.
Further, and equally concerningly, the terms of a transaction support agreement (TSA) with Coupang, Greenoaks and others, which Farfetch entered into on 18 December 2023, risks making it unviable for any other bidders to present an alternative, value-maximizing offer. If Farfetch pursues an alternative transaction, any competing bidder would, in effect, have to pay a US$1 billion fee, reflecting a 1.95x MOIC on undrawn bridge loans, and term loans, and a further US$20 million cash termination fee. Consenting term lenders are being paid a consent fee of 7.5% - materially higher than market practice – to support the transaction, despite its value-destruction.
The Group believes that better value for the assets of Fartetch could be achieved through alternative routes than the proposed sale, including a break-up sale of the assets to interested bidders, several of whom have been publicly identified.
There appears to have been no transparency or governance in this process, which has reportedly left many of Farfetch’s luxury retail partners uncomfortable and considering severing ties. Indeed, on the day it announced the TSA, Farfetch also announced that all of the independent directors of Farfetch Limited had resigned from their positions on the Board, leaving just José Neves, founder, Chairman and CEO, as the sole Board member.
“The Group believes this process sets an incredibly dangerous precedent,” said a spokesperson for the 2027 Ad Hoc Group. “Allowing this transaction to complete fails to maximize the value of the assets of the Company, at a time when at least three other credible parties were publicly reported to be interested in all or parts of the business. The Group is urgently considering appropriate next steps.”
Notes to Editors:
About the 2027 Ad Hoc Group
The 2027 Ad Hoc Group is a group of funds managed by institutional investors managing a combined AUM in excess of US$1 trillion. The Ad Hoc Group of creditors holds over 50% of Farfetch’s 3.75% Convertible Senior Notes due 2027.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240126849710/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
